Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SST-0225 in Delayed Onset Muscle Soreness
NCT02597634Phase 3Completed
- Sponsor
- Strategic Science & Technologies
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibuprofen in delayed onset muscle soreness (DOMS) (2 arms), sponsored by Strategic Science & Technologies. Primary endpoint: Sum of Pain Intensity Differences over 0-24 hours. Started Nov 2015; status: completed.
02
Drugs
ibuprofen
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on NCT02597634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597634.